Robert D Schreiber

List of Publications by Year
in descending order

240 papers	85,324 citations	1027 117 h-index	1189 235 g-index
246 all docs	246 docs citations	246 times ranked	75086 citing authors

#	Article	IF	Citations
1	Cancer Immunoediting: Integrating Immunityâ€™s Roles in Cancer Suppression and Promotion. Science, 2011, 331, 1565-1570.	6.0	4,987
2	Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 2002, 3, 991-998.	7.0	4,290
3	Neoantigens in cancer immunotherapy. Science, 2015, 348, 69-74.	6.0	3,809
4	Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 1990, 348, 334-336.	13.7	3,662
5	HOW CELLS RESPOND TO INTERFERONS. Annual Review of Biochemistry, 1998, 67, 227-264.	5.0	3,630
6	The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 2004, 21, 137-148.	6.6	2,486
7	The Three Es of Cancer Immunoediting. Annual Review of Immunology, 2004, 22, 329-360.	9.5	2,422
8	IFNÎ³ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410, 1107-1111.	13.7	2,400
9	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell, 2015, 162, 1229-1241.	13.5	2,158
10	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	13.7	1,705
11	Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 2011, 29, 235-271.	9.5	1,691
12	Batf3 Deficiency Reveals a Critical Role for CD8Î± ⁺ Dendritic Cells in Cytotoxic T Cell Immunity. Science, 2008, 322, 1097-1100.	6.0	1,665
13	Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAKâ€“STAT Signaling Pathway. Cell, 1996, 84, 431-442.	13.5	1,537
14	Interferons, immunity and cancer immunoediting. Nature Reviews Immunology, 2006, 6, 836-848.	10.6	1,312
15	Demonstration of an interferon Â-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7556-7561.	3.3	1,277
16	The Molecular Cell Biology of Interferon-gamma and its Receptor. Annual Review of Immunology, 1993, 11, 571-611.	9.5	1,270
17	Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 2007, 450, 903-907.	13.7	1,204
18	New insights into cancer immunoediting and its three component phasesâ€”elimination, equilibrium and escape. Current Opinion in Immunology, 2014, 27, 16-25.	2.4	1,163

#	Article	IF	Citations
19	Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science, 1988, 240, 516-518.	6.0	1,122
20	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 2012, 482, 400-404.	13.7	1,075
21	Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes. Immunity, 1996, 4, 25-36.	6.6	1,065
22	Cytokine Signaling in 2002. Cell, 2002, 109, S121-S131.	13.5	978
23	THE IFNÎ³ RECEPTOR:A Paradigm for Cytokine Receptor Signaling. Annual Review of Immunology, 1997, 15, 563-591.	9.5	941
24	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics, 2016, 48, 607-616.	9.4	933
25	Type I interferon is selectively required by dendritic cells for immune rejection of tumors. Journal of Experimental Medicine, 2011, 208, 1989-2003.	4.2	874
26	Cancer cellâ€“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	15.2	823
27	The roles of IFNÎ³ in protection against tumor development and cancer immunoediting. Cytokine and Growth Factor Reviews, 2002, 13, 95-109.	3.2	797
28	Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses. Cell, 1998, 93, 373-383.	13.5	787
29	Impaired response to interferon-Î±/Î² and lethal viral disease in human STAT1 deficiency. Nature Genetics, 2003, 33, 388-391.	9.4	720
30	Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.. Journal of Experimental Medicine, 1977, 146, 257-270.	4.2	704
31	Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity. Advances in Immunology, 2006, 90, 1-50.	1.1	689
32	Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling. Science, 2013, 340, 207-211.	6.0	643
33	Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4.. Journal of Experimental Medicine, 1995, 181, 1755-1762.	4.2	623
34	Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor.. Journal of Experimental Medicine, 1982, 156, 1000-1009.	4.2	594
35	Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature, 1994, 372, 560-563.	13.7	586
36	MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature, 2019, 574, 696-701.	13.7	563

#	Article	IF	Citations
37	Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 7404-7408.	3.3	562
38	Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNÎ³ receptors. Immunity, 1994, 1, 447-456.	6.6	542
39	Stat1-dependent and -independent pathways in IFN-Î³-dependent signaling. Trends in Immunology, 2002, 23, 96-101.	2.9	533
40	A critical function for type I interferons in cancer immunoediting. Nature Immunology, 2005, 6, 722-729.	7.0	516
41	Tumor neoantigens: building a framework for personalized cancer immunotherapy. Journal of Clinical Investigation, 2015, 125, 3413-3421.	3.9	502
42	Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation. Science, 2001, 293, 300-303.	6.0	486
43	Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.. Journal of Experimental Medicine, 1993, 178, 1541-1554.	4.2	470
44	Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7673-7678.	3.3	465
45	A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nature Genetics, 1999, 21, 370-378.	9.4	458
46	Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.. Journal of Experimental Medicine, 1984, 160, 55-74.	4.2	449
47	Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell, 1985, 40, 209-217.	13.5	423
48	Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.. Journal of Experimental Medicine, 1981, 154, 856-867.	4.2	421
49	Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3764-3768.	3.3	416
50	Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91).. EMBO Journal, 1994, 13, 1591-1600.	3.5	395
51	Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation. Journal of Immunology, 2006, 177, 3260-3265.	0.4	390
52	Defective Lymphotoxin-beta Receptor-Induced NF-kappa B Transcriptional Activity in NIK-Deficient Mice. Science, 2001, 291, 2162-2165.	6.0	388
53	Molecular Biology and Chemistry of the Alternative Pathway of Complement. Advances in Immunology, 1980, 29, 1-53.	1.1	381
54	Synergy between Interferon-Î³ and Tumor Necrosis Factor-Î± in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor ÎºB. Journal of Biological Chemistry, 1997, 272, 14899-14907.	1.6	379

#	Article	IF	Citations
55	Compensatory dendritic cell development mediated by BATFâ€“IRF interactions. Nature, 2012, 490, 502-507.	13.7	367
56	Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-GuÃ©rin infection and a sibling with clinical tuberculosis.. Journal of Clinical Investigation, 1997, 100, 2658-2664.	3.9	337
57	Interleukin-10 Receptor Signaling through the JAK-STAT Pathway. Journal of Biological Chemistry, 1999, 274, 16513-16521.	1.6	333
58	Biologic consequences of Stat1-independent IFN signaling. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6680-6685.	3.3	328
59	Natural Immunity: A T-Cell-Independent Pathway of Macrophage Activation, Defined in the scid Mouse. Immunological Reviews, 1991, 124, 5-24.	2.8	322
60	CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-Â. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8633-8638.	3.3	317
61	Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy. Immunity, 2000, 13, 265-276.	6.6	315
62	Interferon Î³ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harbor Perspectives in Biology, 2019, 11, a028480.	2.3	315
63	TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell, 2020, 182, 886-900.e17.	13.5	309
64	Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process.. Journal of Experimental Medicine, 1994, 180, 995-1004.	4.2	302
65	cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature, 2020, 584, 624-629.	13.7	298
66	Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 5430-5434.	3.3	294
67	High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell, 2018, 175, 1014-1030.e19.	13.5	292
68	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	13.5	287
69	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. Journal of Experimental Medicine, 2012, 209, 1869-1882.	4.2	281
70	Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals of the New York Academy of Sciences, 2013, 1284, 1-5.	1.8	272
71	Stat recruitment by tyrosine-phosphorylated cytokine receptors: An ordered reversible affinity-driven process. Immunity, 1995, 2, 677-687.	6.6	271
72	Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Current Opinion in Immunology, 2007, 19, 203-208.	2.4	270

#	Article	IF	Citations
73	Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 652-656.	3.3	270
74	Chronic Tumor Necrosis Factor Alters T Cell Responses by Attenuating T Cell Receptor Signaling. Journal of Experimental Medicine, 1997, 185, 1573-1584.	4.2	268
75	Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function. Journal of Immunology, 2007, 178, 7540-7549.	0.4	261
76	The IÎºB Function of NF-ÎºB2 p100 Controls Stimulated Osteoclastogenesis. Journal of Experimental Medicine, 2003, 198, 771-781.	4.2	260
77	In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood, 1994, 84, 4045-4052.	0.6	255
78	Immune-mediated dormancy: an equilibrium with cancer. Journal of Leukocyte Biology, 2008, 84, 988-993.	1.5	253
79	Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transientin vivo T cell activation. European Journal of Immunology, 1990, 20, 509-515.	1.6	252
80	Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nature Immunology, 2006, 7, 33-39.	7.0	243
81	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunology Research, 2017, 5, 106-117.	1.6	236
82	Stat1-independent regulation of gene expression in response to IFN-Â. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6674-6679.	3.3	231
83	Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. Journal of Clinical Investigation, 2003, 111, 1297-1308.	3.9	225
84	Blocking Monoclonal Antibodies Specific for Mouse IFN-Î±/Î²Receptor Subunit 1 (IFNAR-1) from Mice Immunized byIn VivoHydrodynamic Transfection. Journal of Interferon and Cytokine Research, 2006, 26, 804-819.	0.5	222
85	WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science, 2018, 362, 694-699.	6.0	216
86	Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm.. Journal of Experimental Medicine, 1989, 170, 2141-2146.	4.2	209
87	Ligand-Induced Autoregulation of IFN-gamma Receptor beta Chain Expression in T Helper Cell Subsets. Science, 1995, 270, 1215-1218.	6.0	199
88	Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nature Genetics, 2005, 37, 692-700.	9.4	198
89	FOURTH COMPONENT OF HUMAN COMPLEMENT: DESCRIPTION OF A THREE POLYPEPTIDE CHAIN STRUCTURE. Journal of Experimental Medicine, 1974, 140, 1324-1335.	4.2	191
90	Stat3 Recruitment by Two Distinct Ligand-induced, Tyrosine-phosphorylated Docking Sites in the Interleukin-10 Receptor Intracellular Domain. Journal of Biological Chemistry, 1996, 271, 27954-27961.	1.6	188

#	Article	IF	Citations
91	Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. Journal of Experimental Medicine, 2009, 206, 2967-2976.	4.2	188
92	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Advances in Immunology, 2016, 130, 25-74.	1.1	181
93	Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins.. Journal of Experimental Medicine, 1979, 149, 870-882.	4.2	177
94	Partial Interferonâ€Î³ Receptor Signaling Chain Deficiency in a Patient with Bacille Calmetteâ€CuÃ©rin andMycobacterium abscessusInfection. Journal of Infectious Diseases, 2000, 181, 379-384.	1.9	171
95	Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease. PLoS Genetics, 2006, 2, e131.	1.5	171
96	A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature, 2004, 431, 527-532.	13.7	169
97	Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1978, 75, 3948-3952.	3.3	166
98	Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 3782-3786.	3.3	162
99	CD8Î±+ Dendritic Cells Are an Obligate Cellular Entry Point for Productive Infection by Listeria monocytogenes. Immunity, 2011, 35, 236-248.	6.6	162
100	IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression. Cancer Research, 2005, 65, 3447-3453.	0.4	161
101	Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein.. EMBO Journal, 1996, 15, 1064-1074.	3.5	157
102	STAT1-deficient mice spontaneously develop estrogen receptor Î±-positive luminal mammary carcinomas. Breast Cancer Research, 2012, 14, R16.	2.2	155
103	Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75.. Journal of Experimental Medicine, 1995, 181, 607-617.	4.2	154
104	ERK1 and ERK2 Activate CCAAAT/Enhancer-binding Protein-Î²-dependent Gene Transcription in Response to Interferon-Î³. Journal of Biological Chemistry, 2001, 276, 287-297.	1.6	151
105	Blockade of Interferon Beta, but Not Interferon Alpha, Signaling Controls Persistent Viral Infection. Cell Host and Microbe, 2015, 17, 653-661.	5.1	151
106	Cutting Edge: IFN-Producing Cells Respond to CXCR3 Ligands in the Presence of CXCL12 and Secrete Inflammatory Chemokines upon Activation. Journal of Immunology, 2002, 169, 6079-6083.	0.4	145
107	HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-Î³. Hepatology, 1992, 16, 655-663.	3.6	144
108	Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes To Cells, 1998, 3, 29-37.	0.5	144

#	Article	IF	Citations
109	Timing and Magnitude of Type I Interferon Responses by Distinct Sensors Impact CD8ÂT Cell Exhaustion and Chronic Viral Infection. Cell Host and Microbe, 2012, 11, 631-642.	5.1	140
110	DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature, 2008, 456, 819-823.	13.7	137
111	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. European Journal of Immunology, 1996, 26, 1335-1341.	1.6	135
112	Perforin and Granzymes Have Distinct Roles in Defensive Immunity and Immunopathology. Immunity, 2006, 25, 835-848.	6.6	134
113	Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. Journal of Experimental Medicine, 2011, 208, 2367-2374.	4.2	134
114	HIF-1Î± regulates epithelial inflammation by cell autonomous NFÎºB activation and paracrine stromal remodeling. Blood, 2008, 111, 3343-3354.	0.6	129
115	CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11612-11616.	3.3	128
116	Ligand-Induced Assembly and Activation of the Gamma Interferon Receptor in Intact Cells. Molecular and Cellular Biology, 1996, 16, 3214-3221.	1.1	126
117	Baculovirus Stimulates Antiviral Effects in Mammalian Cells. Journal of Virology, 1999, 73, 9944-9951.	1.5	126
118	Interferon-Î³ and Cancer Immunoediting. Immunologic Research, 2005, 32, 231-246.	1.3	123
119	Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome.. Journal of Clinical Investigation, 1986, 78, 977-982.	3.9	120
120	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
121	Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. Journal of Experimental Medicine, 2005, 201, 681-686.	4.2	118
122	Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide-enhanced radioresistance.. Journal of Experimental Medicine, 1991, 173, 1177-1182.	4.2	117
123	Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.. Journal of Clinical Investigation, 1989, 83, 1253-1257.	3.9	116
124	IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes.. Journal of Clinical Investigation, 1998, 102, 1249-1257.	3.9	116
125	Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.. Journal of Experimental Medicine, 1975, 142, 760-772.	4.2	115
126	Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.. Journal of Experimental Medicine, 1981, 153, 1592-1603.	4.2	111

#	Article	IF	Citations
127	Identification of a functionally important sequence in the C terminus of the interferon-gamma receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11706-11710.	3.3	107
128	Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1011-1015.	3.3	104
129	Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands. Cancer Research, 2010, 70, 490-500.	0.4	104
130	Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77, 559-562.	3.3	103
131	Cloning and expression of the cDNA for the murine interferon gamma receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8497-8501.	3.3	99
132	Antiâ€“IFN-Î±/Î² Receptor Antibody Treatment Ameliorates Disease in Lupus-Predisposed Mice. Journal of Immunology, 2012, 189, 5976-5984.	0.4	99
133	Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins. Cancer Research, 2006, 66, 7301-7309.	0.4	98
134	A molecular concept of the properdin pathway.. Proceedings of the National Academy of Sciences of the United States of America, 1976, 73, 612-616.	3.3	97
135	A Causative Relationship between Mutant IFNgR1 Alleles and Impaired Cellular Response to IFNÎ³ in a Compound Heterozygous Child. American Journal of Human Genetics, 1998, 62, 723-727.	2.6	97
136	Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.. Journal of Experimental Medicine, 1983, 157, 1971-1980.	4.2	96
137	A Temporal Role Of Type I Interferon Signaling in CD8+ T Cell Maturation during Acute West Nile Virus Infection. PLoS Pathogens, 2011, 7, e1002407.	2.1	95
138	Identification of an Interferon-Î³ Receptor Î± Chain Sequence Required for JAK-1 Binding. Journal of Biological Chemistry, 1996, 271, 9-12.	1.6	94
139	IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors. Journal of Immunology, 2006, 176, 905-913.	0.4	94
140	IFN-Î³ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response. Journal of Immunology, 2005, 175, 4433-4440.	0.4	92
141	Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research, 2012, 72, 3987-3996.	0.4	92
142	Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes.. Journal of Clinical Investigation, 1985, 76, 2196-2205.	3.9	91
143	Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5401-5405.	3.3	89
144	Regulation of IFNâ€Î±/Î² genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFNâ€Î±/Î². Genes To Cells, 1996, 1, 995-1005.	0.5	88

#	Article	IF	Citations
145	The odds of immunotherapy success. Science, 2015, 350, 158-159.	6.0	87
146	Tissue-specific targeting of gytokine unresponsiveness in transgenic mice. Immunity, 1995, 3, 657-666.	6.6	84
147	Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunology Research, 2016, 4, 1007-1015.	1.6	84
148	Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection. Journal of Experimental Medicine, 2017, 214, 1153-1167.	4.2	80
149	Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody.. Journal of Experimental Medicine, 1979, 150, 445-454.	4.2	78
150	Vav proteins control MyD88-dependent oxidative burst. Blood, 2007, 109, 3360-3368.	0.6	76
151	A Critical Role for Type I IFN in Arthritis Development followingBorrelia burgdorferiInfection of Mice. Journal of Immunology, 2008, 181, 8492-8503.	0.4	76
152	Critical Role for Interferon Regulatory Factor 3 (IRF-3) and IRF-7 in Type I Interferon-Mediated Control of Murine Norovirus Replication. Journal of Virology, 2012, 86, 13515-13523.	1.5	76
153	Purification and characterization of the human interferon-gamma receptor from placenta.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4837-4841.	3.3	72
154	Ligand-induced Formation of p55 and p75 Tumor Necrosis Factor Receptor Heterocomplexes on Intact Cells. Journal of Biological Chemistry, 1997, 272, 10784-10789.	1.6	72
155	The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. Clinical Immunology and Immunopathology, 1982, 23, 335-357.	2.1	70
156	Prolongation of Cardiac and Islet Allograft Survival by a Blocking Hamster Anti-Mouse CXCR3 Monoclonal Antibody. Transplantation, 2008, 86, 137-147.	0.5	70
157	Interleukin 12 Stimulates IFN-Î³â€“Mediated Inhibition of Tumor-Induced Regulatory T-Cell Proliferation and Enhances Tumor Clearance. Cancer Research, 2009, 69, 8700-8709.	0.4	69
158	Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.. Journal of Clinical Investigation, 1994, 93, 2189-2196.	3.9	69
159	Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins.. Journal of Experimental Medicine, 1978, 148, 1722-1727.	4.2	67
160	Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clinical Immunology and Immunopathology, 1980, 15, 384-396.	2.1	63
161	Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer. Journal of Nuclear Medicine, 2012, 53, 1119-1126.	2.8	63
162	Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.. Journal of Experimental Medicine, 1976, 144, 1062-1075.	4.2	62

#	Article	IF	Citations
163	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	62
164	Identification of the Activator System for Antibody to Toxoplasma as the Classical Complement Pathway. Journal of Infectious Diseases, 1980, 141, 366-369.	1.9	60
165	PREVENTION OF THE GRAFT-VERSUS-HOST REACTION IN NEWBORN MICE BY ANTIBODIES TO TUMOR NECROSIS FACTOR-ALPHA. Transplantation, 1989, 47, 1057-1060.	0.5	60
166	Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway. Nature Medicine, 1999, 5, 1370-1374.	15.2	60
167	The chemistry and biology of complement receptors. Seminars in Immunopathology, 1984, 7, 221-249.	4.0	59
168	Programmable nanoparticle functionalization forin vivotargeting. FASEB Journal, 2013, 27, 255-264.	0.2	58
169	STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-Â in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16209-16214.	3.3	57
170	Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor.. Journal of Experimental Medicine, 1982, 156, 677-689.	4.2	55
171	Functional Cooperation of the Interleukin-2 Receptor Î² Chain and Jak1 in Phosphatidylinositol 3-Kinase Recruitment and Phosphorylation. Molecular and Cellular Biology, 1998, 18, 6416-6422.	1.1	54
172	ABIN-3: a Molecular Basis for Species Divergence in Interleukin-10-Induced Anti-Inflammatory Actions. Molecular and Cellular Biology, 2007, 27, 4603-4616.	1.1	54
173	Enhanced tumorigenesis in HTLV-1 Tax-transgenic mice deficient in interferon-gamma. Blood, 2004, 104, 3305-3311.	0.6	52
174	A Novel c-Jun-dependent Signal Transduction Pathway Necessary for the Transcriptional Activation of Interferon Î³ Response Genes. Journal of Biological Chemistry, 2007, 282, 938-946.	1.6	52
175	Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.. Journal of Clinical Investigation, 1984, 73, 160-170.	3.9	52
176	TAK1 targeting by glucocorticoids determines JNK and IÎºB regulation in Toll-like receptorâ€“stimulated macrophages. Blood, 2010, 115, 1921-1931.	0.6	50
177	Response to interferons and antibacterial innate immunity in the absence of tyrosineâ€phosphorylated <scp>STAT</scp> 1. EMBO Reports, 2016, 17, 367-382.	2.0	50
178	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. OncoImmunology, 2019, 8, e1561106.	2.1	50
179	Identifying the Initiating Events of Anti-ListeriaResponses Using Mice with Conditional Loss of IFN-Î³ Receptor Subunit 1 (IFNGR1). Journal of Immunology, 2013, 191, 4223-4234.	0.4	49
180	NF-ÎºB-Inducing Kinase Regulates Selected Gene Expression in the Nod2 Signaling Pathway. Infection and Immunity, 2006, 74, 2121-2127.	1.0	48

#	Article	IF	Citations
181	Selective Blockade of Interferon-Î± and -Î² Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection. PLoS ONE, 2015, 10, e0128636.	1.1	47
182	Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. International Immunology, 1992, 4, 611-614.	1.8	45
183	CXCR3 Enhances a T-Cellâ€“Dependent Epidermal Proliferative Response and Promotes Skin Tumorigenesis. Cancer Research, 2011, 71, 5707-5716.	0.4	41
184	Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERÎ±+ tumorigenesis. Cell Death and Differentiation, 2014, 21, 234-246.	5.0	41
185	A Novel Role for Stat1 in Phagosome Acidification and Natural Host Resistance to Intracellular Infection by Leishmania major. PLoS Pathogens, 2009, 5, e1000381.	2.1	40
186	The Lymphotoxin LTÎ±1Î²2 Controls Postnatal and Adult Spleen Marginal Sinus Vascular Structure and Function. Immunity, 2009, 30, 408-420.	6.6	40
187	Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to) Tj ETQq1 1 0.784314 rgBT /Overlock 10 antibody to interferon gamma.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1591-1595.	3.3	39
188	Dual Requirement of Cytokine and Activation Receptor Triggering for Cytotoxic Control of Murine Cytomegalovirus by NK Cells. PLoS Pathogens, 2015, 11, e1005323.	2.1	37
189	Macrophage I-A/I-E expression and macrophage-stimulating lymphokines in murine lupus. Cellular Immunology, 1984, 87, 92-100.	1.4	36
190	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. Oncotarget, 2018, 9, 4109-4119.	0.8	34
191	Stat-1 Is Not Essential for Inhibition of B Lymphopoiesis by Type I IFNs. Journal of Immunology, 2000, 165, 2362-2366.	0.4	32
192	A completely foreign receptor can mediate an interferon-gamma-like response. EMBO Journal, 2001, 20, 5431-5442.	3.5	30
193	Hypocomplementemic Glomerulonephritis in an Infant and Mother. American Journal of Nephrology, 1987, 7, 470-477.	1.4	28
194	Cancer Immunoediting of the NK Group 2D Ligand H60a. Journal of Immunology, 2011, 187, 3538-3545.	0.4	26
195	Enumeration of cytokine-secreting cells at the single-cell level. European Journal of Immunology, 1989, 19, 1591-1597.	1.6	25
196	Strain-Specific Variation in Murine Natural Killer Gene Complex Contributes to Differences in Immunosurveillance for Urethane-Induced Lung Cancer. Cancer Research, 2012, 72, 4311-4317.	0.4	25
197	cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1. Cancer Immunology Research, 2022, 10, 920-931.	1.6	24
198	C3 modified at the thiolester site: Acquisition of reactivity with cellular C3b receptors. Bioscience Reports, 1981, 1, 873-880.	1.1	23

#	Article	IF	Citations
199	Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. Cell Reports, 2016, 17, 249-260.	2.9	21
200	The biology and biochemistry of interferon-gamma and its receptor. Gastroenterologia Japonica, 1993, 28, 88-94.	0.4	20
201	Leprosy: Altered Complement Receptors in Disseminated Disease. Journal of Investigative Dermatology, 1985, 85, S58-S61.	0.3	19
202	Up-Regulation of Gamma Interferon Receptors on the Human Monocytic Cell Line U937 by 1,25-Dihydroxyvitamin D3 and Granulocyte-Macrophage Colony Stimulating Factor. Journal of Leukocyte Biology, 1988, 44, 187-191.	1.5	19
203	NKG2Dâ€“NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo. Journal of Immunology, 2016, 196, 4805-4813.	0.4	19
204	Characterization and expression of the human leukocyte-common antigen (CD45) gene contained in yeast artificial chromosomes. Genomics, 1991, 10, 756-764.	1.3	18
205	Response to 'A cancer immunosurveillance controversy'. Nature Immunology, 2004, 5, 4-5.	7.0	18
206	The structure and function of interferon-Î³ receptors. International Journal of Immunopharmacology, 1992, 14, 413-419.	1.1	17
207	Loss of DAP12 and FcRÎ³ Drives Exaggerated IL-12 Production and CD8+ T Cell Response by CCR2+ Mo-DCs. PLoS ONE, 2013, 8, e76145.	1.1	17
208	Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins.. Journal of Experimental Medicine, 1987, 165, 777-798.	4.2	15
209	IFN-Î³ produced in vivo during the first two days is critical for resolution of murine Leishmania major infections. Microbial Pathogenesis, 1993, 14, 495-500.	1.3	15
210	Enumeration andCharacterization of Human Killer and Natural Killer Cells by a Modified Single-Cell Assay. Scandinavian Journal of Immunology, 1984, 19, 529-539.	1.3	14
211	Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. OncoImmunology, 2016, 5, e1186314.	2.1	13
212	Response and Resistance to Interferons and Interacting Cytokines. Journal of the National Cancer Institute, 1995, 87, 257-264.	3.0	11
213	Deficiency of erythrocyte C3b receptor (CR1) in AIDS and AIDS-related syndromes. Bioscience Reports, 1986, 6, 81-86.	1.1	9
214	Interferon-Î³. , 2003, , 567-601.		9
215	A dual function of <scp>NKG</scp>2<scp>D</scp> ligands in <scp>NK</scp>â€cell activation. European Journal of Immunology, 2012, 42, 2452-2458.	1.6	9
216	Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent. PLoS ONE, 2015, 10, e0129895.	1.1	9

#	Article	IF	Citations
217	An Important Role for CD4⁺T Cells in Adaptive Immunity to Toxoplasma gondii in Mice Lacking the Transcription Factor Batf3. MSphere, 2020, 5, .	1.3	8
218	Measurement of Mouse and Human Interferon Î³. Current Protocols in Immunology, 2000, 37, Unit 6.8.	3.6	7
219	Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immunity, 2005, 5 Suppl 1, 1.	3.2	7
220	Novel ERÎ± positive breast cancer model with estrogen independent growth in the bone microenvironment. Oncotarget, 2016, 7, 49751-49764.	0.8	6
221	The role of antibody and complement in lysing virus-infected cells. Medical Microbiology and Immunology, 1982, 170, 221-227.	2.6	5
222	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2021, 39, TPS192-TPS192.	0.8	4
223	Bcl6-Independent In Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection. Journal of Immunology, 2021, 207, 125-132.	0.4	4
224	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, 5068-5068.	0.8	4
225	Macrophage activation factor from EL-4, a murine T-cell line: Antigenic characterization by hamster monoclonal antibodies to murine interferon-Î³. Cellular Immunology, 1987, 107, 340-347.	1.4	3
226	Immunology at 2000. Immunity, 1999, 11, 649-651.	6.6	3
227	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3
228	Fresh Beginnings. Cancer Immunology Research, 2016, 4, 1-2.	1.6	3
229	The Chemistry and Biology of Complement Receptors. , 1985, , 115-143.		3
230	Tumor necrosis factor-alpha prevents rejection of islet xenografts (rat to mouse). Diabetes, 1993, 42, 651-657.	0.3	3
231	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. OncoImmunology, 2016, 5, e1186323.	2.1	2
232	Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity. Cancer Research, 2012, 72, 526-526.	0.4	2
233	The molecular basis of IFNÎ³ action. Growth Factors and Cytokines in Health and Disease, 1997, , 521-556.	0.2	1
234	The Continuing Evolution of Immunology at Washington University. Immunologic Research, 2005, 32, 001-004.	1.3	1

#	Article	IF	Citations
235	IL-12 Stimulates Interferon-Gamma Mediated Inhibition of Tumor-Induced Regulatory T Cell Proliferation and Enhances Tumor Clearance. Blood, 2008, 112, 2558-2558.	0.6	1
236	The Future of Immunity. Immunity, 1996, 5, 503.	6.6	0
237	O032 Timing and magnitude of Type I interferon responses by distinct viral sensors impact CD8 T cell exhaustion and chronic infection. Cytokine, 2012, 59, 512.	1.4	0
238	Preface. Advances in Immunology, 2016, 130, xi-xiii.	1.1	0
239	IFNÎ³ Receptor-STAT1 Signaling and Cancer Immunoediting. , 2003, , 399-418.		0
240	A New Year, A New Initiative. Cancer Immunology Research, 2022, 10, 2-2.	1.6	0